[Ip-health] Parexel opens another early phase unit in South Africa

[Joana Ramos]

This is a multi-part message in MIME format.
--
Presumably there is a typo in the 2nd sentence:
> South Africa has a treatment na=EFve and generically diverse population
and the author meant to say "genetically diverse".....


Here's the link to the patient recruitment section of Parexel's website:

http://www.parexel.com/early-phase/Volunteer-to-Participate.html


Joana

-----------------------------------------------------------------------

http://tinyurl.com/yh5tpp7


Parexel opens another early phase unit in South Africa
By Nick Taylor, 24-Feb-2010

Related topics: Globalisation, Clinical evolution, Clinical Development,
Phase I-II

Parexel has opened a 40 bed early phase clinical trial unit in South
Africa, increasing its Phase I capabilities in the country and adding to
its patient recruitment focused SuperSites network.

South Africa has a treatment na=EFve and generically diverse population
which makes it easier for contract research organisations (CRO) to
quickly recruit patients for clinical trials. Parexel has recognised and
benefited from this, leading to it adding a third early phase unit in
the country.

The new site in Port Elizabeth brings Parexel=92s global early phase
capacity, including the two other South African units in Bloemfontein
and George, to 580 beds. Parexel believes this is among the largest
early phase capacities in the world.

At the Port Elizabeth site Parexel will conduct early phase studies in
patients, from first in man to proof of concept. This is the core focus
of the unit but it will also conduct a variety of studies on healthy
volunteers.

Patients and healthy volunteers will be recruited using the tools and
techniques Parexel deploys at its SuperSites. These include using
dedicated patient recruitment specialists, building relationships with
local health care professionals and drawing on its database.

Fast recruitment is generally welcomed because of its positive impact on
drug development timelines, an important issue for pharma and biotech,
but Parexel believes there are additional benefits.

"Increasing the number of patients per site and reducing the overall
number of sites in a study serves to decrease variability--improving
study quality and reproducibility", explained Michelle Middle, corporate
vice president and worldwide head of early phase at Parexel.

The Port Elizabeth unit will be integrated into Parexel=92s early phase
network, which spans three continents, by using harmonised systems that
help handle complex global studies.


-------------------------
Joana Ramos, MSW
Cancer Resources & Advocacy
Seattle WA USA
+1-206-229-2420
http://ramoslink.info/
www.bmtbasics.org
http://healthwatched.org

--
[ jdr.vcf of type text/x-vcard deleted ]